scholarly journals Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study

2013 ◽  
Vol 2013 ◽  
pp. 1-14 ◽  
Author(s):  
Susanna Jakobson Mo ◽  
Jan Linder ◽  
Lars Forsgren ◽  
Henrik Holmberg ◽  
Anne Larsson ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Progressive Supranuclear Palsy ◽  
Healthy Controls ◽  
Follow Up Study ◽  
The Mean ◽  
One Year ◽  
Over Time

We prospectively evaluated the diagnostic contribution of123I-FP-Cit (DAT) and123I-IBZM (IBZM) SPECT in 29 patients with Parkinson's disease (PD) (74.4±4.2years) and 28 patients with atypical parkinsonian diseases (APD) (74.3±9.2years). Twelve had multiple system atrophy (MSA) and 16 progressive supranuclear palsy (PSP). Sixteen age-matched healthy controls (HC) were included. DAT and IBZM SPECTs were made at baseline and after 1 year in all PD patients and in 20 (DAT) and 18 (IBZM) of the APD patients, and after 3 years in 22 (DAT) and 17 (IBZM) of the PD patients and in 10 (DAT) and 10 (IBZM) of the APD patients. The relative DAT uptake decrease was faster in PD and PSP than in HC and MSA. In PSP the DAT uptake was lower than in MSA after 1 year but not after 3 years. Baseline IBZM uptake was not significantly different between patients and HC or between PD and APD. One year after initiated dopaminergic treatment the mean IBZM uptake in the MSA patients remained high compared to PSP and after 3 years compared to PD, PSP, and HC. Thus, the pattern of uptake of these ligands over time may be of value in discriminating between these diagnoses.

Impulsive and compulsive behaviors in Parkinson's disease: A one-year follow-up study

2011 ◽  
Vol 310 (1-2) ◽  
pp. 197-201 ◽  
Author(s):  
Asunción Ávila ◽  
Xavier Cardona ◽  
Montse Martín-Baranera ◽  
Juan Bello ◽  
Francesc Sastre
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Follow Up Study ◽  
Compulsive Behaviors ◽  
One Year

scholarly journals Diagnostic accuracy of glabellar tap sign for Parkinson’s disease

2021 ◽  
Author(s):  
Simo Nuuttila ◽  
Mikael Eklund ◽  
Juho Joutsa ◽  
Elina Jaakkola ◽  
Elina Mäkinen ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Diagnostic Value ◽  
Clinical Test ◽  
Diagnostic Validity ◽  
Healthy Controls ◽  
Validity And Reliability ◽  
Dopaminergic Activity ◽  
Over Time

AbstractGlabellar tap or reflex (GR) is an old bedside clinical test used in the diagnostics of Parkinson’s disease (PD), but its diagnostic value is unclear. This study examines the diagnostic validity and reliability of GR in PD in relation to brain dopaminergic activity. GR was performed on 161 patients with PD, 47 patients with essential tremor (ET) and 40 healthy controls immediately prior to dopamine transporter (DAT) [123I]FP-CIT SPECT scanning. The binding ratios were investigated with consideration of the GR result (normal/abnormal). In addition, the consistency of the GR was investigated with 89 patients after a mean follow-up of 2.2 years. PD and ET patients had higher GR scores than healthy controls (p < 0.001), but there was no difference in GR between PD and ET patients (p = 0.09). There were no differences in the ratio of abnormal to normal GRs between the PD and ET groups (73% vs. 64% abnormal, respectively, p = 0.13) or in DAT binding between PD patients with abnormal and normal GRs (p > 0.36). Over follow-up, the GR changed from abnormal to normal in 20% of PD patients despite the presence of clinically typical disease. The sensitivity and specificity of GR for differentiating PD from ET were 78.3% and 36.2%, respectively. Although GR has been used by clinicians in the diagnostics of PD, it does not separate PD from ET. It also shows considerable inconsistency over time, and abnormal GR has no relationship with dopamine loss. Its usefulness should be tested for other clinical diagnostic purposes.

III.P3 One year follow-up study for hallucinations in patients with Parkinson's Disease

2006 ◽  
Vol 12 ◽  
pp. 30-31
Author(s):  
M. Svetel ◽  
T. Smiljkovic ◽  
T. Pekmezovic ◽  
N. Dragasevic ◽  
V. Kostic
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Follow Up Study ◽  
One Year

III.5 One year follow-up study for hallucinations in patients with Parkinson's Disease

2006 ◽  
Vol 12 ◽  
pp. 10
Author(s):  
M. Svetel ◽  
T. Smiljkovic ◽  
T. Pekmezovic ◽  
N. Dragasevic ◽  
V. Kostic
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Follow Up Study ◽  
One Year

scholarly journals Change in Non-motor Symptoms in Parkinson’s Disease and Essential Tremor Patients: A One-year Follow-up Study

2014 ◽  
Vol 4 (0) ◽  
pp. 216 ◽  
Author(s):  
Maurizio Giorelli ◽  
Junia Bagnoli ◽  
Luigi Consiglio ◽  
Pasquale Difazio ◽  
Daniela Zizza ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Essential Tremor ◽  
Motor Symptoms ◽  
Follow Up Study ◽  
One Year ◽  
Non Motor Symptoms

Development of standardized regression-based formulas to assess meaningful cognitive change in early Parkinson’s disease

2020 ◽  
Author(s):  
Hannah L Combs ◽  
Kate A Wyman-Chick ◽  
Lauren O Erickson ◽  
Michele K York
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Test Scores ◽  
Prediction Models ◽  
Early Stage ◽  
Cognitive Change ◽  
Cognitive Test ◽  
Healthy Controls ◽  
Change Over Time ◽  
Over Time

Abstract Objective Longitudinal assessment of cognitive and emotional functioning in patients with Parkinson’s disease (PD) is helpful in tracking progression of the disease, developing treatment plans, evaluating outcomes, and educating patients and families. Determining whether change over time is meaningful in neurodegenerative conditions, such as PD, can be difficult as repeat assessment of neuropsychological functioning is impacted by factors outside of cognitive change. Regression-based prediction formulas are one method by which clinicians and researchers can determine whether an observed change is meaningful. The purpose of the current study was to develop and validate regression-based prediction models of cognitive and emotional test scores for participants with early-stage idiopathic PD and healthy controls (HC) enrolled in the Parkinson’s Progression Markers Initiative (PPMI). Methods Participants with de novo PD and HC were identified retrospectively from the PPMI archival database. Data from baseline testing and 12-month follow-up were utilized in this study. In total, 688 total participants were included in the present study (NPD = 508; NHC = 185). Subjects from both groups were randomly divided into development (70%) and validation (30%) subsets. Results Early-stage idiopathic PD patients and healthy controls were similar at baseline. Regression-based models were developed for all cognitive and self-report mood measures within both populations. Within the validation subset, the predicted and observed cognitive test scores did not significantly differ, except for semantic fluency. Conclusions The prediction models can serve as useful tools for researchers and clinicians to study clinically meaningful cognitive and mood change over time in PD.

scholarly journals A Comparison of Pain between Parkinson’s Disease and Multiple System Atrophy: A Clinical Cross-Sectional Survey

2019 ◽  
Vol 2019 ◽  
pp. 1-6
Author(s):  
He-Yang You ◽  
Lei Wu ◽  
Hai-Ting Yang ◽  
Chen Yang ◽  
Xiao-Ling Ding
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Multiple System Atrophy ◽  
Rating Scale ◽  
Depression Scale ◽  
Healthy Controls ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Disease Rating ◽  
Vas Scores

Background. Pain is frequent in Parkinson’s disease (PD) and Parkinson-plus syndrome. This study aimed to assess the prevalence, characteristics, therapy (especially the effect of dopaminergic therapy), and associated symptoms of pain in Parkinson's disease and multiple system atrophy (MSA) patients. Methods. Seventy-one PD patients, sixty-five MSA patients, and forty age-matched healthy controls were enrolled and evaluated by using the German pain questionnaire and visual analogue scale (VAS). In addition, the influence of pain in PD patients on anxiety, depression, and the quality of life was assessed with the Hospital Anxiety and Depression Scale (HADS) and Parkinson’s Disease Questionnaire (PDQ-39). Results. Compared to that of the healthy controls, the PD and MSA patients had a significantly higher presence of pain (P<0.01, P<0.01). PD patients had a higher presence of pain than MSA patients (P=0.007). No difference in VAS scores was observed between the PD and MSA patients (P=0.148). A total of 21 PD patients (42.85%) with pain and 13 MSA patients (43.33%) with pain received treatment. A total of 13 PD patients with pain and 6 MSA patients with pain had an improved pain intensity after using dopaminergic medication. The differences in the disease duration, Hoehn and Yahr stages, and scores on the Unified Parkinson’s Disease Rating Scale motor score, HAD-D, HAD-A, and PDQ-39 were significant between the PD patients with and without pain. Conclusion. PD and MSA patients are prone to pain with insufficient treatment. Pain interventions should be provided as soon as possible to improve the patient’s life.

Sign in / Sign up

Export Citation Format

Share Document